We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

135 hedge funds and large institutions have $855M invested in CRISPR Therapeutics in 2018 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

442% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 12

192% more capital invested

Capital invested by funds: $293M → $855M (+$562M)

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

63% more funds holding

Funds holding: 83 → 135 (+52)

31% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 26

9.37% more ownership

Funds ownership: 30.47% → 39.84% (+9.4%)

72% less call options, than puts

Call options by funds: $8.4M | Put options by funds: $30.4M

Holders
135
Holders Change
+52
Holders Change %
+62.65%
% of All Funds
3.09%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.11%
New
65
Increased
34
Reduced
26
Closed
12
Calls
$8.4M
Puts
$30.4M
Net Calls
-$22M
Net Calls Change
-$23.7M

Top Buyers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
+$190M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$38M
3
MWNA
Marshall Wace North America
New York
+$19.7M
4
Wells Fargo
Wells Fargo
California
+$18.2M
5
NMC
NEA Management Company
Maryland
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
CCP
Clough Capital Partners
Massachusetts
-$13.6M
2
GTP
Global Thematic Partners
New York
-$11.6M
3
FCM
Farallon Capital Management
California
-$8.82M
4
OM
Opaleye Management
Massachusetts
-$6.6M
5
GTC
Ghost Tree Capital
New York
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
26
Nicholas Investment Partners
California
$3.68M +$3.32M +80,490 New
AIM
27
ARK Investment Management
Florida
$3.32M +$1.7M +41,146 +131%
UBS Group
28
UBS Group
Switzerland
$2.71M +$2.35M +57,025 +2,406%
FAAS
29
First Allied Advisory Services
California
$2.69M +$2.43M +58,905 New
IIM
30
Ipswich Investment Management
Massachusetts
$2.61M +$364K +8,818 +18%
Citadel Advisors
31
Citadel Advisors
Florida
$2.45M +$573K +13,885 +35%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$2.04M +$1.77M +42,795 +2,208%
Victory Capital Management
33
Victory Capital Management
Texas
$1.95M +$1.76M +42,670 New
Vanguard Group
34
Vanguard Group
Pennsylvania
$1.89M +$994K +24,076 +139%
AI
35
Axiom Investors
Connecticut
$1.63M +$1.47M +35,688 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$1.57M +$1.42M +34,400 New
PFGIA
37
Patriot Financial Group Insurance Agency
Massachusetts
$1.48M +$1.21M +29,217 +597%
Goldman Sachs
38
Goldman Sachs
New York
$1.26M +$202K +4,890 +22%
Geode Capital Management
39
Geode Capital Management
Massachusetts
$1.26M +$21.7K +525 +2%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$1.22M +$526K +12,751 +92%
USAA
41
United Services Automobile Association
Texas
$1.21M -$714K -17,300 -40%
Ameriprise
42
Ameriprise
Minnesota
$1.17M +$1.12M +27,133 New
CIBC World Market
43
CIBC World Market
Ontario, Canada
$1.16M +$1.04M +25,298 New
AG
44
Artal Group
Luxembourg
$1.14M -$1.03M -25,000 -50%
Deutsche Bank
45
Deutsche Bank
Germany
$1.11M -$1.4M -33,830 -58%
EGI
46
EAM Global Investors
California
$1.09M +$983K +23,820 New
EIM
47
Essex Investment Management
Massachusetts
$996K -$1.21M -29,290 -57%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$995K +$899K +21,778 New
ProShare Advisors
49
ProShare Advisors
Maryland
$973K -$34K -823 -4%
ARTA
50
A.R.T. Advisors
New York
$944K -$157K -3,800 -16%
1
2
3 4 5

CRSP Hedge Fund Activity: Q1 2018 in Review

135 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2018, worth a combined $855M — up 192% from $293M a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new CRSP positions and 12 closed out — a net gain of 53 holders — while 34 added to existing stakes and 26 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $190M. The largest seller was Clough Capital Partners, cutting an estimated $13.6M.

  • 135 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2018, up from 83 in Q4 2017.
  • Funds reported $855M of CRISPR Therapeutics stock for Q1 2018, up 192% quarter-over-quarter.
  • 65 funds opened new CRISPR Therapeutics positions in Q1 2018 and 12 closed out, a net change of +53 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2018 was Versant Venture Management, an estimated $190M added.
  • The largest CRISPR Therapeutics seller in Q1 2018 was Clough Capital Partners, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2018.